Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective <scp>QOLIXANE</scp> trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registrySalah‐Eddin Al‐Batran, Ursula Vehling‐Kaiser, Lars Hahn et al.|International Journal of Cancer|2020Cited by 21
“CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO.Hans‐Joachim Schmoll, Alexander Stein, Fabian Maximilian Meinert et al.|Journal of Clinical Oncology|2017Cited by 19
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trialHans‐Joachim Schmoll, Joseph Tintelnot, Julia Mann et al.|British Journal of Cancer|2023Cited by 11
CHARTA: FOLFOX+bevacizumab +/- irinotecan in advanced colorectal cancer (CRC)—Final results of the randomized phase II trial of the AIO (KRK 0209).Hans‐Joachim Schmoll, Alexander Stein, Benjamin Garlipp et al.|Journal of Clinical Oncology|2017Cited by 9
Impact of FOLFOXIRI and bevacizumab (bev) compared to FOLFOX and bev on health related quality of life (HRQOL) in patients with metastatic colorectal cancer (MCRC): Analysis of the CHARTA-AIO 0209 trial.Julia Quidde, Alexander Stein, Hans‐Joachim Schmoll et al.|Journal of Clinical Oncology|2017Cited by 2